Eudowood Division of Pediatric Respiratory Sciences
Baltimore, Maryland, 21287, United States
NCT Number: NCT00325767
The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Baltimore, Maryland, 21287, United States
In healthy lungs, inhaled insoluble material such as bacteria, viruses, antigens, and toxins deposit in the tracheobronchial airway mucus and are removed from the lung in a matter of hours by mucociliary clearance (MCC). When MCC is overwhelmed or impaired, some mucus can be removed by mechanical or cough clearance (CC). Impairment of MCC typically leads to the accumulation of mucus in the airways, and this in turn is associated with acute infections, chronic bacterial colonization, and chronic inflammation.
Racemic albuterol has been shown to stimulate MCC in various patient populations. Inhaled and subcutaneous terbutaline has also been shown to stimulate MCC in healthy subjects. We hypothesize that levalbuterol will be more potent than racemic albuterol in enhancing MCC and CC in healthy subjects.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Johns Hopkins University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05755932
Mucociliary Clearance
Kansas City, Kansas, United States
View Trial DetailsNCT05875025
Mucociliary Clearance
Glasgow, United Kingdom
View Trial DetailsNCT00902707
Mucociliary Clearance
Chapel Hill, North Carolina, United States
View Trial DetailsNCT00999531
Airway Hydration, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Melbourne, Victoria, Australia
View Trial Details